Tim Kopra spent over 244 days in space, and now he's using his tech background to invest in emerging energy companies. Courtesy of Tim Kopra

When Tim Kopra returned from space in 2009 after he served as flight engineer on NASA's Expedition 20, he was ready to transition into civilian life. The Army vet went to business school, received his MBA in 2013, and started thinking about his next steps here on earth.

That is, until he was called back by NASA to serve as flight engineer then commander of the ISS in Expedition 46/47. He landed in June of 2016 after spending a career total of 244 days in space.

The timing was right this time around for Kopra. A former classmate of his, Ernst Theodor Sack, had worked at a Riverstone Holdings for a decade and had realized the potential for funding smaller, more niche startups. Sack was ready to branch out on his own, and Kopra was looking for his next career opportunity too.

That's how the two partnered up to create Blue Bear Capital, an investment fund that invests in data-driven technology companies in the energy supply chain.

"You can think of it as Silicon Valley tech, IoT, analytics, machine learning, SaaS business models applied to oil and gas, wind, solar, and energy storage," Kopra says.

The energy industry has been known to be slow to adopt new technology, like analytics, machine learning, and the Internet of Things, Kopra says, but Blue Bear's goal is to find the startups creating cutting edge technology and help them gain a footing in the industry.

"In order to adopt new technology, our view is that it has to be able to demonstrate clear value proposition upfront — not something that promises to improve operations down the line. It needs to happen relatively quickly."

Blue Bear capital closed its fund in the fourth quarter of 2018 with a total of eight investments. Kopra spoke with InnovationMap on how he's merged his space career into a tech investment guru.

InnovationMap: What sort of experience do you bring in to your investment responsibilities from your Army and NASA days?

Tim Kopra: On face value, it may sound like an odd match, taking someone with a tech and operational background and putting them in venture, but quite frankly it feels very familiar to me because my career has really been focused on working on complex technology and operations with very small teams. It's not just a theoretical understanding of the technology, but understanding how to use the technology and how it works.

It's something that over time, when you work with different kinds of aircraft or experiments on the Space Station or the space suits we use on space walks or the robotics system we used, you really develop a strong sense of how we as humans are able to work with technology and improve the functions we have in our jobs. That's a valuable aspect I bring to the table.

There's the operational component too. You can have great technology, but if it's not well matched to its job and implementation, it's not going to have the ability to solve the problems it was intended for. Third component is with small teams. I've worked with teams of two to 10 to 30 to several hundred — you recognize the need for people to work more effectively together.

I was on the last couple of astronaut selection committees. Our most recent one was going through 18,300 and select 12. Our job during the last portion of the selection is interviewing the last 50 or so. Those people competing for those spots are rock solid when it comes to their technical background and operational experience. The one thing we were asking ourselves as the interview committee was, "Who'd you want to go camping with?" It's the matter of the kind of people you can spend time with and be effective with. When we look at companies to invest in, we are looking for good small teams like that.

IM: How has Houston's tech ecosystem changed throughout your career?

TK: When we started in January of 2017, we saw one conference every few months that was involved in innovation and new technology and its application in oil and gas. Whereas now, it's pretty much every month that there's a major event about applying new technology in the industry.

IM: So, how has the city been for you as an investor?

TK: Obviously, Houston is the center for traditional energy and oil and gas. One thing that has been notable over our journey is the increased involvement in corporate venture funds. And, then the number of startups — it's a growing number and there's plenty of room for growth when it comes to energy startups. We've definitely seen an improvement in the types of technology provided and the number of startups emerging.

IM: Do you feel like the relationship you have with corporate VCs is competitive or collaborative?

TK: I think that the environment for venture capital in Houston in particular is very collaborative. When it comes to the corporate VCs, we're aligned because often times they are looking for companies farther along and then secondly, we're happy to co-invest with corporate teams. There are plenty of deals to go around, and we think working together we can definitely succeed.

IM: What types of companies are you looking for?

TK: We consider companies that are early revenue companies. We focus on data-driven technology companies, but they need to have recurring commercial revenue, so not just pilots.

IM: What's next for Blue Bear?

TK: We recently closed the fund, and what that means is we need to deploy the capital. We've invested in eight companies and had one exit, which we are excited about.

What we try to do is find the absolute best in class within a sector in which we invest.

IM: What keeps you up at night, as it pertains to your business?

TK: It's a very dynamic world. We have to keep track of macro trends and understand where the market is going. That has everything to do from the price of oil to government incentives to what large companies are investing in. I wouldn't say that it keeps us awake at night, but there's so many facets of the business that can impact what we do — positively and negatively. But we are constantly keeping track of what's going on in the world and what's going on in our sector.

The one thing we are most focused on right now is maintaining deal flow that we've been able to achieve. Going through the thousand or so companies we have over the past couple of years has been an extremely arduous task, but it's necessary for us to be able to understand the market.

We need to be as diligent as we have been over the past couple years. It's a really exciting space to work in, and we just need to maintain that level of excitement.

------

Portions of this interview have been edited.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

UH med school granted $2M gift to offer student scholarships

scholarship gift

A new scholarship endowment aims to support students in the University of Houston’s recently established medical school.

The University of Houston’s Tilman J. Fertitta Family College of Medicine received a planned estate gift commitment estimated at $2.1 million to establish the Bob Diehl and Teresa Evans Diehl Scholarship Endowment. The scholarship will assist full-time medical students who demonstrate financial need and meet academic standards.

“Endowed scholarships like this do more than ease the burden of tuition—they empower our students to focus on learning, leadership and compassionate care,” Jonathan McCullers, UH vice president of health affairs and dean of the Fertitta College of Medicine, said in a news release. “We are deeply grateful to the Diehls for their vision and commitment to expanding access to health care through education.”

The endowment aims to provide annual scholarship support for students enrolled in the Fertitta College of Medicine. The gift also aligns with the university's fundraising initiative focused on expanding opportunities for students, known as Can’t Stop Houston: The Centennial Campaign, which works to expand research ahead of UH’s 100th anniversary next year.

The Diehls are both graduates from UH, and Bob Diehl spent 38 years working at UPS.

“It brings me happiness to know that my endowment will make a difference in young people's lives and in the communities that will need those future doctors,” he said in the release.

The Fertitta College of Medicine welcomed its inaugural class of 30 students in 2020 and expects classes to grow to 120 students in the coming years, according to UH. The university believes scholarship opportunities will be crucial for students to pursue medical education despite financial challenges.

“The Diehl family’s generosity will open doors for talented future physicians who are called to serve our communities but may otherwise face financial barriers to pursuing a medical education,” McCullers added.

9 Houston universities boast best grad programs of 2026, per U.S. News

making the grade

Nine Houston-area universities are earning new national acclaim in a report of the best graduate schools in the U.S. for 2026.

U.S. News & World Report annually publishes its national "Best Graduate Schools" rankings in early April, which comprehensively rank graduate programs across business, education, engineering, law, health, and many others.

New for the 2026 edition, the publication updated its rankings across 12 health disciplines — only physician assistant and social work were excluded — and "the first full refresh" of doctoral science programs since 2022. U.S. News also revived its Master's in Fine Arts rankings for the first time since 2020.

"We know a graduate degree is a major commitment,” said LaMont Jones, Ed.D., managing editor of Education at U.S. News. “That is why we are dedicated to methodologies that thoroughly examine a wide range of factors, from research excellence to career success. These rankings are a powerful tool for prospective students, offering clarity and confidence as they approach their most critical educational choice."

This is how the nine local schools ranked, statewide and nationally, and how they compared with last year's national ranking:

Rice University

  • Brown School of Engineering – No. 3 best graduate engineering school in Texas; No. 25 nationally (up from No. 26 last year)
  • Jones Graduate School of Business – No. 3 best business school in Texas; No. 29 nationally (unchanged)

Several of Rice’s doctoral science programs were among the 30 best in the country, including earth sciences (No. 20), chemistry (No. 22), biostatistics (No. 25), mathematics (No. 26), statistics (No. 27), and physics (No. 28). The Ph.D. biological sciences program tied as 55th best nationwide. Rice’s public affairs program tied for No. 107 nationally.

University of Houston

  • Cullen College of Engineering – No. 5 best graduate engineering school in Texas; tied for No. 71 nationally (up from No. 72 last year)
  • College of Education – No. 5 best graduate education school in Texas; No. 95 nationally (down from No. 81 last year)
  • UH Law Center – No. 5 best law school in Texas; No. 54 nationally (up from No. 63 last year)

The University of Houston has the 31st best pharmacy program in the country, its speech-language pathology program tied for No. 54 nationally, and the clinical psychology program tied as 65th best in the U.S. In the doctoral sciences rankings, UH’s earth sciences program ranked No. 80 nationally, the physics program tied for No. 81, the chemistry program ranked 84th, and the mathematics program ranked No. 87. The Ph.D. biological sciences program ranked as the 104th best in the nation. UH’s public affairs program tied as 80th best nationally. The university also has the 106th best fine arts program in the nation.

University of Houston, Clear Lake

  • College of Education – No. 12 best graduate education school in Texas; No. 164 nationally (up from No. 166 last year)

University of Texas Health Science Center (UT Health Houston)

  • Cizik School of Nursing – No. 2 best master’s in nursing program in Texas; No. 32 nationally (up from No. 41 last year)
  • McGovern Medical School – Tier 2 best research medical school in the U.S.

UT Health Houston’s public health program tied for No. 31 nationwide, and the health care management program tied for No. 47. The Cizik School of Nursing’s nurse anesthesia program tied as 49th best in the country. In the doctoral sciences rankings, the university’s biostatistics program tied as the 25th best nationwide.

University of Texas Medical Branch, Galveston

  • Sealy School of Medicine – Tier 2 best medical research school in the U.S.

UT Medical Branch’s occupational therapy program tied for No. 41 nationally, the physical therapy program tied for No. 57, and the university tied for the 60th best nurse anesthesia program in the U.S. The public health program tied for No. 89 nationally. In the doctoral sciences rankings, the university’s biostatistics program tied for No. 70 nationally.

Prairie View A&M University

  • College of Nursing – No. 5 best master’s in nursing program in Texas; No. 104 nationally (unchanged)

South Texas College of Law Houston

  • No. 7 best law school in Texas; No. 128 nationally (up from No. 138 last year)

Texas Southern University

  • College of Education – No. 17 best graduate education school in Texas; No. 219 nationally (down from No. 178-195 last year)

TSU’s pharmacy program tied for No. 120 nationally.

University of Texas MD Anderson
UT MD Anderson’s doctoral biostatistics program tied as the 17th best nationally, and the doctoral biological sciences program tied for No. 50.

---

This article originally appeared on CultureMap.com.

Houston medtech firm secures $30M for neurosurgical robot

stroke surgery

Robotic neurosurgery is an exciting new frontier in medicine, and Houston-based medtech firm XCath is leading the charge with its revolutionary Iris robotic system. The company announced in March that it had secured $30 million in Series C funding to continue developing systems to tackle blood clots in the human brain.

“We are grateful to our investors for their conviction in our shared mission to improve clinical outcomes for patients impacted by endovascular diseases,” Eduardo Fonseca, CEO of XCath, said in a news release. “In 2025, the XCath team advanced the frontiers of endovascular robotics. This funding accelerates our commitment to expanding access to life-saving care so that where a patient lives no longer determines whether they live.”

XCath–which also has campuses in Pangyo, South Korea–has already achieved a number of remarkable firsts in robotic neurosurgery. The Iris is the only endovascular robotic system currently in development to perform intracranial navigation or neurointerventional treatment, and is the only robot in the world to have performed an intracranial neurovascular procedure involving the robotic manipulation of three devices.

These new Series C funds, which bring the company's total investment to $92 million, will go toward developing a clinical telerobot capable of performing a mechanical thrombectomy. This would bring unprecedented accuracy and precision to the surgical removal of brain clots, significantly reducing the risk of neurosurgery.

“Robotic surgery succeeds when innovation is paired with practical execution,” Dr. Fred Moll, chairman of the XCath board of directors, said in the release. “XCath has built a promising technology foundation, and just as importantly, a team that values rigor and appreciates perspective. I’m excited to support them as they take on the mission of globalizing access to gold-standard care for stroke patients.”

In November 2025, the Iris debuted under the control of Dr. Vitor Mendes Pereira at The Panama Clinic in Panama City, alongside local Principal Investigator Dr. Anastasio Ameijeiras Sibauste. It was only the second time in human history that a robot had been used for intracranial neurovascular intervention, and it established Iris as a viable technology in the fight against stroke.

“Treatment of stroke and other neurovascular diseases represents one of the most significant financial opportunities in healthcare, supported by positive reimbursement dynamics and strong demand from health systems,” Nicholas Drysdale, CFO of XCath, added in the release. “With our continued investor support and disciplined capital deployment, XCath is positioned to build a category-leading platform in endovascular robotics”.